Richard A. Basile
Richard Basile is Chief Executive Officer of BioPontis Alliance. BioPharmaceutical executive with 30 yrs commercial international experience within early stage and Fortune 100 Pharma/Biotech including licensing, M&A, product development and launch in anti infective, cardiovascular, immunological, dermatologic and metabolic disease segments. Mr. Basile has participated in the launch of more than 15 pharmaceutical and biological products including two top 5 global products, ciprofloxacin and nifedipine, as well as leading biotechnology and protein therapeutic products including rfVIII and IV immune globulin. Appointed VP of corporate strategy, finance, and business development of a $1.2 billion international biologics business unit with responsibility for licensing, M&A, JV, financial planning and reporting, and R&D Alliances, Mr. Basile played a leadership role on the senior executive team in the consolidation of a new global business unit at Bayer AG. (Bayer Biologicals). Prior to that appointment, Mr. Basile served in several senior marketing , sales and strategic marketing capacities’ at Bayer Pharmaceuticals, and was President and General Manager of a Bayer subsidiary, Rhein Chemie Corporation. More recently, Mr. Basile was the founding CEO of Entegrion (formerly Hemocellular Therapeutics), an early stage biotech company founded on UNC-CH invention in homeostasis, Executive VP at MylanBertek, and was the global commercial head of Diosynth Biotechnology, part of Organon Biosciences where he also served on the executive management team of Organon (now Merck & Co) responsible for biotechnology business development, with focus on oncology and immunology.
BioPontis Alliance is led by industry veterans who are committed to advancing novel biological research by bringing their collective experience in technical, regulatory, commercial, and scientific development into early stage biomedical product creation; a commitment fueled by the clear understanding that medicine will not advance without a solution to the feasibility gap.